Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB decreased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,300 shares of the company’s stock after selling 9,400 shares during the period. Handelsbanken Fonder AB’s holdings in Krystal Biotech were worth $13,363,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. State Street Corp increased its stake in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after buying an additional 119,936 shares during the period. Geode Capital Management LLC increased its stake in Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after buying an additional 11,411 shares during the period. Franklin Resources Inc. increased its stake in Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after buying an additional 62,178 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Krystal Biotech by 9.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock valued at $43,727,000 after buying an additional 19,777 shares during the period. Finally, Braidwell LP boosted its position in shares of Krystal Biotech by 57.4% during the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after purchasing an additional 61,512 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KRYS. HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $210.00.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Trading Up 2.9 %

Shares of KRYS stock opened at $187.86 on Friday. Krystal Biotech, Inc. has a 1 year low of $107.50 and a 1 year high of $219.34. The firm’s fifty day simple moving average is $157.37 and its 200 day simple moving average is $175.23. The firm has a market capitalization of $5.40 billion, a P/E ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the previous year, the firm posted $0.30 earnings per share. Krystal Biotech’s revenue was up 116.4% compared to the same quarter last year. Equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).